Resection of hepatocellular carcinoma in cirrhotic patients: longterm results of a prospective study11No competing interests declared.

Gouillat, C.; Manganas, D.; Saguier, G; Duque-Campos, René; Bérard, P.

doi:10.1016/s1072-7515(99)00142-8

Cited by 38 publications

(13 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…the cumulative probability of avoiding both death and disease recurrence) predominantly fall within the following ranges: 50-80% at 1 year, 30-50% at 3 years, 15-40% at 5 years and 8-20% at 10 years. 158,166,173,174,[176][177][178][179][180][181][182][183][184][185][186][187][188][189][190][191][192][193] …”

Section: Disease Recurrencementioning

confidence: 99%

“…It should be noted that these data categorise patients according to the primary liver disease specified at the time of listing; this has the important implication that the 'HCC' category represents a minority of patients with tumours on 176,178,179,190,193,[415][416][417][418][419][420][421] • 11 insufficient sample size (n < 50) 171,172,186,205,411,[422][423][424][425][426][427] • Four included a substantial proportion of non-cirrhotic cases 155,165,428,429 • Five included a substantial proportion of large tumours (>5 cm) 166 …”

Section: Waiting List For Liver Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

150

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

Section: Disease Recurrencementioning

confidence: 99%

Section: Waiting List For Liver Transplantationmentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

150

108

View full text Add to dashboard Cite

show abstract

“…Insbesondere das präoperative Vorhandensein von Aszites weist jedoch auf einen protrahierten und somit komplizierteren postoperativen Verlauf hin. Farkas/Schlitt von 30-50% erreicht werden [19][20][21]. In einer aktuellen japanischen Registeranalyse [2] mit mehr als 20 000 Patienten lag das rezidivfreie 10-Jahres-Überleben bei 22%.…”

Section: Leberresektion In Zirrhoseunclassified

Resektion und Lebertransplantation bei hepatozellulärem Karzinom

Farkas¹

2013

Visc Med

View full text Add to dashboard Cite

Hintergrund: Kurative Therapieverfahren für das hepatozelluläre Karzinom (HCC) sind die Resektion und die Lebertransplantation. Grundlage für die Therapieentscheidung ist bisher die Klassifikation der Barcelona Clinic Liver Cancer Group (BCLC). Methode: Basis dieser Arbeit ist eine selektive Literaturübersicht zur Therapie des HCC. Leitlinien verschiedener Fachgesellschaften wurden einbezogen und aktuelle Arbeiten zu neuen chirurgischen Techniken besonders berücksichtigt. Ergebnisse: Primär resektable HCCs sollen reseziert werden. Für die Resektion kommen alle Patienten in adäquatem Allgemeinzustand ohne Zirrhose oder mit Child-A-Zirrhose ohne ausgeprägte portale Hypertension in Betracht. Hierbei ist von entscheidender Bedeutung, dass über die Möglichkeit der Resektabilität in einem ausgewiesenen Leberzentrum befunden wird. Auf die Leber beschränkte Rezidive können erneut operiert oder für eine Lebertransplantation gelistet werden. Techniken zur erweiterten Leberresektion und laparoskopische Verfahren finden zunehmend Anwendung und müssen weiter evaluiert werden. Schlussfolgerung: Neben der Resektion ist die Lebertransplantation inzwischen eine Standardtherapie für HCCs in Zirrhose. Innerhalb der Mailand-Kriterien können nach der Transplantation 5-Jahres-Überlebensraten von 70-90% erreicht werden. Allerdings erfordern der zunehmende Organmangel und die daraus resultierenden längeren Wartezeiten mit der Gefahr des Tumorprogresses ein Umdenken. So können Patienten, die für eine Transplantation infragekommen, nicht nur zum Bridging bis zur Transplantation reseziert werden, sondern auch, um eine biologische Stratifizierung durchzuführen. Unter engmaschigem Monitoring kann dann erst bei Auftreten eines Rezidivs eine «Rescue»-Transplantation durchgeführt werden. Jedoch werden auch Patienten mit fortgeschritteneren Tumoren, die nicht oder erst zu spät transplantiert werden können, zunehmend mit guten Ergebnissen reseziert. Somit könnten die Kriterien für eine Resektion im Rahmen der BCLC-Klassifikation erweitert werden.

show abstract

“…Patients with tumors >5 cm in size but adequate liver function and only mild portal hypertension can be treated by resection after presentation to the tumor board (GCP). In selected groups of patients treated in this way the 5-year survival rate is 30% to 50% (28). Nevertheless, a recurrence rate of up to 50% must be expected after resection of HCC in a cirrhotic liver (29).…”

Section: Patients With Liver Cirrhosismentioning

confidence: 99%